-
- Rohit Malik
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Lalit Patel
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- John R. Prensner
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Yang Shi
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Matthew K. Iyer
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Shruthi Subramaniyan
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Alexander Carley
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Yashar S. Niknafs
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Anirban Sahu
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Sumin Han
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Teng Ma
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Meilan Liu
- 4Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
-
- Irfan A. Asangani
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Xiaojun Jing
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Xuhong Cao
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Saravana M. Dhanasekaran
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Dan R. Robinson
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Felix Y. Feng
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
-
- Arul M. Chinnaiyan
- 1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
説明
<jats:title>Abstract</jats:title> <jats:p>Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer–associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.</jats:p> <jats:p>Implications: This study identifies PCAT29 as the first androgen receptor–repressed lncRNA that functions as a tumor suppressor and that its loss may identify a subset of patients at higher risk for disease recurrence.</jats:p> <jats:p>Visual Overview: http://mcr.aacrjournals.org/content/early/2014/07/31/1541-7786.MCR-14-0257/F1.large.jpg. Mol Cancer Res; 12(8); 1081–7. ©2014 AACR.</jats:p>
収録刊行物
-
- Molecular Cancer Research
-
Molecular Cancer Research 12 (8), 1081-1087, 2014-08-14
American Association for Cancer Research (AACR)
